P. Cook

发表

Development of an anti-core lipopolysaccharide vaccine for the prevention and treatment of sepsis.

S. Opal, A. Cross, J. Drabick, 2004, Vaccine.

Phase I study of detoxified Escherichia coli J5 lipopolysaccharide (J5dLPS)/group B meningococcal outer membrane protein (OMP) complex vaccine in human subjects.

S. Opal, A. Cross, H. S. Warren, 2003, Vaccine.

Use of Real-Time PCR and Fluorimetry To Detect Lamivudine Resistance-Associated Mutations in Hepatitis B Virus

D. Pillay, P. Cane, D. Mutimer, 1999, Antimicrobial Agents and Chemotherapy.

Genetic diversity of integrase (IN) sequences in antiretroviral treatment-naive and treatment-experienced HIV type 2 patients.

J. Workman, E. Smit, B. Ferns, 2008, AIDS research and human retroviruses.

Analysis of Hepatitis B Virus Quasispecies Changes during Emergence and Reversion of Lamivudine Resistance in Liver Transplantation

D. Pillay, G. Beards, P. Cane, 1999, Antiviral therapy.

Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy.

D. Pillay, P. Cane, E. Elias, 2000, The Journal of infectious diseases.

The prevalence of transmitted antiretroviral drug resistance in treatment‐naïve patients and factors influencing first‐line treatment regimen selection

B. Young, P. Benson, A. Scribner, 2008, HIV medicine.

Dynamics of raltegravir resistance profile in an HIV type 2-infected patient.

N. Garrett, J. Workman, E. Smit, 2009, AIDS research and human retroviruses.

Mixed populations in influenza virus vaccine strains.

J. Wood, R. Newman, J. Robertson, 1994, Vaccine.

Replicative advantage in tissue culture of egg-adapted influenza virus over tissue-culture derived virus: implications for vaccine manufacture.

A. Attwell, J. Robertson, S. Williams, 1995, Vaccine.

Dynamics of raltegravir resistance profile in an HIV type 2-infected patient.

N. Garrett, J. Workman, E. Smit, 2009, AIDS research and human retroviruses.